The Pharma Titans' Dance of Acquisition Recent rumors of a potential AstraZeneca Bristol Myers Squibb merger have sent shockwaves through the pharmaceutical industry.
The exact motivations behind this move remain unclear, leaving many wondering if it's a genuine attempt to reshape the global biopharma landscape or merely a fleeting flirtation.
AstraZeneca, still recovering from its 2016 acquisition of Medimmune, has been actively expanding its portfolio and seeking to solidify its position as a leader in the industry.